{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:31:37Z","timestamp":1758817897938},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,8,25]],"date-time":"2015-08-25T00:00:00Z","timestamp":1440460800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s12094-015-1385-9","type":"journal-article","created":{"date-parts":[[2015,8,24]],"date-time":"2015-08-24T04:05:10Z","timestamp":1440389110000},"page":"413-417","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Concurrent radiotherapy with S-1 plus cisplatin versus concurrent radiotherapy with cisplatin alone for the treatment of locally advanced cervical carcinoma: a pilot randomised controlled trial"],"prefix":"10.1007","volume":"18","author":[{"given":"Z.","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,25]]},"reference":[{"key":"1385_CR1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0167-8140(03)00197-X","volume":"68","author":"JM Kirwan","year":"2003","unstructured":"Kirwan JM, Symonds P, Green JA, Tierney J, Collingwood M, Williams CJ. A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol. 2003;68:217\u201326.","journal-title":"Radiother Oncol"},{"key":"1385_CR2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0305-7372(03)00117-8","volume":"29","author":"JH Maduro","year":"2003","unstructured":"Maduro JH, Pras E, Willemse PH, de Vries EG. Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treat Rev. 2003;29:471\u201388.","journal-title":"Cancer Treat Rev"},{"key":"1385_CR3","unstructured":"National Cancer Institutes. Guidelines gynaecologic tumours: cervical carcinoma [Internet]. Bethesda, MD: National Cancer Institutes; 2004 [cited 2011 Jun 20]. http:\/\/www.cancer.gov ."},{"key":"1385_CR4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clon.2005.09.001","volume":"18","author":"M King","year":"2006","unstructured":"King M, McConkey C, Latief TN, Hartley A, Fernando I. Improved survival after concurrent weekly cisplatin and radiotherapy for cervical carcinoma with assessment of acute and late side-effects. Clin Oncol (R Coll Radiol). 2006;18:38\u201345.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"1385_CR5","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJM199904153401509","volume":"340","author":"GM Thomas","year":"1999","unstructured":"Thomas GM. Improved treatment for cervical cancer: concurrent chemotherapy and radiotherapy. N Engl J Med. 1999;340:1198\u2013200.","journal-title":"N Engl J Med"},{"key":"1385_CR6","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/00001813-199607000-00010","volume":"7","author":"T Shirasaka","year":"1996","unstructured":"Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7:548\u201357.","journal-title":"Anticancer Drugs"},{"issue":"5","key":"1385_CR7","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00280-013-2137-6","volume":"71","author":"M Yunokawa","year":"2013","unstructured":"Yunokawa M, Katsumata N, Yamamoto H, Kodaira M, Yonemori K, Shimizu C, et al. A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer. Cancer Chemother Pharmacol. 2013;71(5):1369\u201374.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"1385_CR8","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/annonc\/mdq602","volume":"22","author":"N Katsumata","year":"2011","unstructured":"Katsumata N, Hirai Y, Kamiura S, Sugiyama T, Kokawa K, Hatae M, et al. Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer. Ann Oncol. 2011;22(6):1353\u20137.","journal-title":"Ann Oncol"},{"issue":"25","key":"1385_CR9","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1097\/MD.0000000000000164","volume":"93","author":"H Liu","year":"2014","unstructured":"Liu H, Chen X, Sun J, Gao P, Song Y, Zhang N, et al. The efficacy and toxicity of paclitaxel plus S-1 compared with paclitaxel plus 5-FU for advanced gastric cancer: a PRISMA systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2014;93(25):e164.","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"1385_CR10","first-page":"1313","volume":"41","author":"T Okuno","year":"2014","unstructured":"Okuno T, Shirotsuki J, Murahashi K, Sawada T. Advanced gastric cancer (stage IV) leading to perforation during chemotherapy with S-1 plus cisplatin. Gan To Kagaku Ryoho. 2014;41(10):1313\u20135.","journal-title":"Gan To Kagaku Ryoho"},{"key":"1385_CR11","first-page":"146530","volume":"2014","author":"J Ye","year":"2014","unstructured":"Ye J, Chen J, Ge L, Liu A, Zhou S. Effectiveness and safety of S-1-based therapy compared with 5-fluorouracil-based therapy for advanced colorectal cancer: a meta-analysis. Gastroenterol Res Pract. 2014;2014:146530.","journal-title":"Gastroenterol Res Pract"},{"issue":"12","key":"1385_CR12","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1517\/14656566.2014.937706","volume":"15","author":"Y Miyamoto","year":"2014","unstructured":"Miyamoto Y, Sakamoto Y, Yoshida N, Baba H. Efficacy of S-1 in colorectal cancer. Expert Opin Pharmacother. 2014;15(12):1761\u201370.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"1385_CR13","first-page":"209","volume":"34","author":"Y Fujimoto","year":"2014","unstructured":"Fujimoto Y, Kato S, Itoh Y, Naganawa S, Nakashima T. A phase I study of concurrent chemoradiotherapy using oral S-1 for head and neck cancer. Anticancer Res. 2014;34(1):209\u201313.","journal-title":"Anticancer Res"},{"issue":"12","key":"1385_CR14","first-page":"5699","volume":"33","author":"H Hayashi","year":"2013","unstructured":"Hayashi H, Okamoto I, Ueda S, Tanaka K, Okamoto K, Kawakami H, et al. Phase I pharmacokinetic study of S-1 granules and nedaplatin for advanced\u00a0head and neck cancer. Anticancer Res. 2013;33(12):5699\u2013705.","journal-title":"Anticancer Res"},{"issue":"13","key":"1385_CR15","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1517\/14656566.2014.945424","volume":"15","author":"M Kawahara","year":"2014","unstructured":"Kawahara M. Efficacy of S-1 in non-small cell lung cancer. Expert Opin Pharmacother. 2014;15(13):1927\u201342.","journal-title":"Expert Opin Pharmacother"},{"issue":"16","key":"1385_CR16","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1016\/j.ejca.2014.07.024","volume":"50","author":"K Aoe","year":"2014","unstructured":"Aoe K, Takigawa N, Hotta K, Maeda T, Kishino D, Nogami N, et al. A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0801. Eur J Cancer. 2014;50(16):2783\u201390.","journal-title":"Eur J Cancer"},{"key":"1385_CR17","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1186\/1471-2407-13-583","volume":"13","author":"YW Moon","year":"2013","unstructured":"Moon YW, Lee S, Park BW, Kim EK, Kim SI, Koo JS, et al. S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in\u00a0breast cancer: phase II trial. BMC Cancer. 2013;13:583.","journal-title":"BMC Cancer"},{"issue":"10","key":"1385_CR18","first-page":"1221","volume":"41","author":"Y Yamamoto","year":"2014","unstructured":"Yamamoto Y, Nishimura R, Tanigawa T, Kawano I, Hayashi K, Kuramoto M, et al. Efficacy and safety of TS-1 monotherapy for advanced\/metastatic breast cancer\u2014an observational study by the Kumamoto Breast Cancer Cooperative Group (KBCCG). Gan To Kagaku Ryoho. 2014;41(10):1221\u20135.","journal-title":"Gan To Kagaku Ryoho"},{"issue":"4","key":"1385_CR19","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00280-013-2265-z","volume":"72","author":"H Song","year":"2013","unstructured":"Song H, Han B, Park CK, Kim JH, Jeon JY, Kim IG, et al. Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2013;72(4):845\u201352.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"1385_CR20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00280-013-2323-6","volume":"73","author":"H Yamaue","year":"2014","unstructured":"Yamaue H, Satoi S, Kanbe T, Miyazawa M, Tani M, Kawai M, et al. Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2014;73(1):97\u2013102.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"1385_CR21","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/cas.12218","volume":"104","author":"C Morizane","year":"2013","unstructured":"Morizane C, Okusaka T, Mizusawa J, Takashima A, Ueno M, Ikeda M, et al. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci. 2013;104(9):1211\u20136.","journal-title":"Cancer Sci"},{"issue":"5","key":"1385_CR22","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00280-013-2106-0","volume":"71","author":"E Suzuki","year":"2013","unstructured":"Suzuki E, Ikeda M, Okusaka T, Nakamori S, Ohkawa S, Nagakawa T, et al. A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer. Cancer Chemother Pharmacol. 2013;71(5):1141\u20136.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1385_CR23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205\u201316.","journal-title":"J Natl Cancer Inst"},{"key":"1385_CR24","unstructured":"Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events v3.0. 2006, Aug 9. http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf . Accessed on 4 Aug 2015."}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-015-1385-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-015-1385-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-015-1385-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:51:47Z","timestamp":1559433107000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-015-1385-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,25]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["1385"],"URL":"https:\/\/doi.org\/10.1007\/s12094-015-1385-9","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,25]]}}}